Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease-Reference-Cited by-同舟云学术

Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease

Published:2023-06 Issue: Volume:183 Page:109618
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

He Kewen,Hong David S.,Tang Chad,Sezen Duygu^ORCID,Cox Livia^ORCID,Maleki Aurian,Bertolet Genevieve^ORCID,Nguyen Quynh-Nhu,Comeaux Nathan I.,Schuda Lily,Chen Dawei,Welsh James W.

Funder

Bristol-Myers Squibb Company

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference35 articles.

1. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: A review;Arbour;J Am Med Assoc,2019

2. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events;Weber;Oncologist,2007

3. CTLA-4 blockade: therapeutic potential in cancer treatments;Tarhini;Onco Targets Ther,2010

4. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

5. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial;Antonia;Lancet Oncol,2016

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination treatment with anti-HER2 therapeutic antibody RC48, PD-1 inhibitor, radiotherapy, and granulocyte macrophage-colony stimulating factor (GM-CSF) in patient with metastatic gastric cancer: a case report;Frontiers in Immunology;2024-02-01